Y MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial

DSpace Repository

Y MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial

Author: Raab, Marc S.; Engelhardt, Monika; Blank, Antje; Goldschmidt, Hartmut; Agis, Hermine; Blau, Igor W.; Einsele, Hermann; Ferstl, Barbara; Schub, Natalie; Roellig, Christoph; Weisel, Katja; Winderlich, Mark; Griese, Janine; Haertle, Stefan; Weirather, Johannes; Jarutat, Tiantom; Peschel, Christian; Chatterjee, Manik
Tübinger Autor(en):
Weisel, Katja
Published in: Lancet Haematology (2020), Bd. 7, H. 5, S. E381-E394
Verlagsangabe: Elsevier Sci Ltd
Language: English
Full text: http://dx.doi.org/10.1016/S2352-3026(19)30249-2
ISSN: 2352-3026
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)